Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX 77030, USA.
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX 77030, USA.
Mol Ther. 2021 Feb 3;29(2):505-520. doi: 10.1016/j.ymthe.2020.10.023. Epub 2020 Oct 31.
Immunotherapy has recently garnered success with the induction of clinical responses in tumors, which are traditionally associated with poor outcomes. Chimeric antigen receptor T (CAR-T) cells and oncolytic viruses (OVs) have emerged as promising cancer immunotherapy agents. Herein, we provide an overview of the current clinical status of CAR-T cell and OV therapies. While preclinical studies have demonstrated curative potential, the benefit of CAR-T cells and OVs as single-agent treatments remains limited to a subset of patients. Combinations of different targeted therapies may be required to achieve efficient, durable responses against heterogeneous tumors, as well as the microenvironment. Using a combinatorial approach to take advantage of the unique features of CAR-T cells and OVs with other treatments can produce additive therapeutic effects. This review also discusses ongoing clinical evaluations of these combination strategies for improved outcomes in treatment of resistant malignancies.
免疫疗法最近在诱导肿瘤临床反应方面取得了成功，而这些肿瘤传统上与预后不良相关。嵌合抗原受体 T 细胞（CAR-T 细胞）和溶瘤病毒（OVs）已成为有前途的癌症免疫疗法药物。本文综述了 CAR-T 细胞和 OV 治疗的当前临床现状。虽然临床前研究已经证明了其潜在的治疗效果，但 CAR-T 细胞和 OVs 作为单一药物治疗的益处仍然仅限于一部分患者。为了实现对异质性肿瘤以及微环境的高效、持久反应，可能需要组合不同的靶向治疗。采用组合方法利用 CAR-T 细胞和 OVs 的独特特性与其他治疗方法相结合，可以产生附加的治疗效果。本文还讨论了这些联合策略的临床评估，以提高耐药性恶性肿瘤的治疗效果。
